-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NNV1 in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NNV1 in Glioblastoma Multiforme (GBM) Drug Details: NNV1 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tolinapant in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tolinapant in Glioblastoma Multiforme (GBM) Drug Details: Tolinapant (ASTX-660) (AT-IAP) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TVI-Brain-1 in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TVI-Brain-1 in Glioblastoma Multiforme (GBM) Drug Details: TVI-Brain-1 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Deruxtecan in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab Deruxtecan in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Trastuzumab deruxtecan (Enhertu, Detrastuzumab) composed of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aminolevulinic Acid Hydrochloride in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Aminolevulinic Acid Hydrochloride in Glioblastoma Multiforme (GBM) Drug Details: Aminolevulinic acid hydrochloride (Alacare/ Effala /...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – WSD-0922 in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. WSD-0922 in Glioblastoma Multiforme (GBM) Drug Details: WSD-0922 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MK-0482 in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MK-0482 in Glioblastoma Multiforme (GBM) Drug Details: MK-0482 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Dexamethasone Sodium Phosphate in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dexamethasone Sodium Phosphate in Glioblastoma Multiforme (GBM) Drug Details: Dexamethasone sodium phosphate (AVM-0703) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AZD-1390 in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AZD-1390 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: AZD-1390 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Sotigalimab in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Sotigalimab in Glioblastoma Multiforme (GBM) Drug Details: Sotigalimab (APX-005M) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Azeliragon in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azeliragon in Glioblastoma Multiforme (GBM) Drug Details: Azeliragon is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Denifanstat in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Denifanstat in Glioblastoma Multiforme (GBM) Drug Details: Denifanstat (TVB-2640) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Glioblastoma Multiforme (GBM) Drug Details: Lurbinectedin (Zepzelca) is a synthetic tetrahydropyrrolo [4, 3,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Glioblastoma Multiforme (GBM) Drug Details: Pegargiminase (ADI-PEG 20) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Elenagen in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Elenagen in Glioblastoma Multiforme (GBM) Drug Details: Elenagen is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Pegargiminase (ADI-PEG 20) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ITI-1001 in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ITI-1001 in Glioblastoma Multiforme (GBM) Drug Details: ITI-1001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ibudilast in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ibudilast in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Ibudilast (Ketas) is an anti-inflammatory and neuroprotective...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Relatlimab in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Relatlimab in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Relatlimab (BMS-986016) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Cemiplimab (Libtayo) is an anti-neoplastic agent. It...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.